Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8+ T Cell Responses
Figure 1
CD8+ T cell response after heterologous prime-boost with archaeosomes and live vectors. Mice were vaccinated (subcutaneously) with Ms-OVA (20 μg OVA entrapped in Ms archaeosomes, 94.1 nm average size, 38 μg/mg loading), or 104 CFU of live LM-OVA or BCG-OVA. Prime-boost regimens involved the same Ms-OVA vaccine given on days 0 and 30, or heterologous boost on day 30 with the BCG-OVA or LM-OVA vector. The CD8+ T cell response was evaluated based on the percentage of OVA257–264 tetramer positive cells in the blood (a, b) and in vivo CTL response (c). (a) Representative scatter plots showing tetramer positive cells on day 7 after a single injection (top panel) or after prime-boost on day 37 (bottom panel). The square gate indicates percentage of tetramer positive cells in the blood of immunized mice. (b, c), Mean ± SD of 5 mice per group. *Response was statistically significant from single dose group by student’s t-test ().
